Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia (Q48262695)

From Wikidata

Jump to navigation Jump to search

scientific article published on 18 May 2011

Language	Label	Description	Also known as
English	Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia	scientific article published on 18 May 2011

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

Inhibition of cerebral type 1 cannabinoid receptors is associated with impaired auditory mismatch negativity generation in the ketamine model of schizophrenia (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

0 references

0 references

0 references

cannabinoid receptor

0 references

Ida S Haussleiter

object named as

Ida S Haussleiter

2

0 references

7

object named as

Georg Juckel

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

author name string

Patrik Roser

1

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

Hee-Jeong Chong

3

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

Christoph Maier

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

Wolfram Kawohl

5

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

Christine Norra

6

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

publication date

18 May 2011

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

number of pages

10

1 reference

based on heuristic

inferred from page(s)

Psychopharmacology

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

218

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

4

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

611-620

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

Cannabinoid receptor antagonists counteract sensorimotor gating deficits in the phencyclidine model of psychosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cannabinoids and psychosis

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Isolation and structure of a brain constituent that binds to the cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Isolation, Structure, and Partial Synthesis of an Active Constituent of Hashish

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Pharmacological models in healthy volunteers: their use in the clinical development of psychotropic drugs

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Testing the glutamate hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The interplay of cannabinoid and NMDA glutamate receptor systems in humans: preliminary evidence of interactive effects of cannabidiol and ketamine in healthy human subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Mismatch negativity generation in the human 5HT2A agonist and NMDA antagonist model of psychosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cannabinoid receptor localization in brain

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Role of cortical N-methyl-D-aspartate receptors in auditory sensory memory and mismatch negativity generation: implications for schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Acute effects of Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory evoked mismatch negativity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Stimulation of endocannabinoid formation in brain slice cultures through activation of group I metabotropic glutamate receptors.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Effects of haloperidol on selective attention: a combined whole-head MEG and high-resolution EEG study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Dopamine modulates involuntary attention shifting and reorienting: an electromagnetic study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

NMDA receptor antagonists ketamine and PCP have direct effects on the dopamine D(2) and serotonin 5-HT(2)receptors-implications for models of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Molecular composition of the endocannabinoid system at glutamatergic synapses.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cannabinoids inhibit the release of [3H]glutamate from rodent hippocampal synaptosomes via a novel CB1 receptor-independent action

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Involvement of cannabinoid receptors in the regulation of neurotransmitter release in the rodent striatum: a combined immunochemical and pharmacological analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The effect of methylphenidate on auditory information processing in healthy volunteers: a combined EEG/MEG study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Effect of ketamine on the neuromagnetic mismatch field in healthy humans.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Acute dopamine D(1) and D(2) receptor stimulation does not modulate mismatch negativity (MMN) in healthy human subjects

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Acute dopamine and/or serotonin depletion does not modulate mismatch negativity (MMN) in healthy human participants

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cognitive consequences of cannabis use: comparison with abuse of stimulants and heroin with regard to attention, memory and executive functions

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

NMDA receptor function and human cognition: the effects of ketamine in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The psychotomimetic states inventory (PSI): measuring psychotic-type experiences from ketamine and cannabis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Placebo-controlled evaluation of four novel compounds for the treatment of schizophrenia and schizoaffective disorder

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Attention and mismatch negativity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The assessment and analysis of handedness: The Edinburgh inventory

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Glutamate receptor dysfunction and schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

NMDA receptor hypofunction model of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

The effects of a sub-anaesthetic dose of ketamine on human selective attention.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Memory-based comparison process not attenuated by haloperidol: a combined MEG and EEG study

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Psychiatric safety of ketamine in psychopharmacology research

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Modelling prefrontal cortex deficits in schizophrenia: implications for treatment

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

SR141716A, a potent and selective antagonist of the brain cannabinoid receptor

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Auditory mismatch negativity deficits in long-term heavy cannabis users.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Phencyclidine and glutamate agonist LY379268 stimulate dopamine D2High receptors: D2 basis for schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Dopamine receptor contribution to the action of PCP, LSD and ketamine psychotomimetics

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Dopamine D2High receptors stimulated by phencyclidines, lysergic acid diethylamide, salvinorin A, and modafinil

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Using an animal model of deficient sensorimotor gating to study the pathophysiology and new treatments of schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Neurophysiological endophenotypes of schizophrenia: the viability of selected candidate measures

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Mismatch negativity in schizophrenia: a meta-analysis.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

How specific are deficits in mismatch negativity generation to schizophrenia?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Electrophysiological indices of automatic and controlled auditory information processing in first-episode, recent-onset and chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Spatio-temporal source imaging reveals subcomponents of the human auditory mismatch negativity in the cingulum and right inferior temporal gyrus.

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

What are the functional consequences of neurocognitive deficits in schizophrenia?

1 reference

https://api.crossref.org/works/10.1007%2FS00213-011-2352-Y

21 January 2018

Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The mismatch negativity: a powerful tool for cognitive neuroscience

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoids modulate synaptic strength and plasticity at glutamatergic synapses of rat prefrontal cortex pyramidal neurons.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Neurocognitive impairment in schizophrenia and how it affects treatment options

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pharmacokinetics of ketamine in man

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for using human event-related potentials to study cognition: recording standards and publication criteria

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabis and cognitive dysfunction: parallels with endophenotypes of schizophrenia?

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures.

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The glutamate synapse in neuropsychiatric disorders. Focus on schizophrenia and Alzheimer's disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Delta9-tetrahydrocannabinol acts as a partial agonist to modulate glutamatergic synaptic transmission between rat hippocampal neurons in culture

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/21590281

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S00213-011-2352-Y

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 February 2018

http://europepmc.org/abstract/MED/21590281

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q48262695&oldid=2209268152"